Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. - Wikidata - awgldk - TriplyDB

Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism.

Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism.

http://www.wikidata.org/entity/Q35230227

about

Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques Anti-Lymphoma Monoclonal Antibodies: Making Better Antibodies and Making Antibodies Better Complement in monoclonal antibody therapy of cancer Translating basic mechanisms of IgG effector activity into next generation cancer therapies Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies Improving natural killer cell cancer immunotherapy Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL c Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients Immunomodulatory activity of orphan drug Elmiron® in female B6C3F1/N mice.Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells.Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone Antibody-Dependent NK Cell Activation Is Associated with Late Kidney Allograft Dysfunction and the Complement-Independent Alloreactive Potential of Donor-Specific Antibodies Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17).Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production.Targeting natural killer cells and natural killer T cells in cancer.Fc-fusion proteins: new developments and future perspectives.The role of natural killer cells in multiple sclerosis and their therapeutic implications.At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias.Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients.Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTXM83 and the Originator Rituximab.The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.Assessment of physicochemical properties of rituximab related to its immunomodulatory activity.Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells.Development of immunomonitoring of antibody‑dependent cellular cytotoxicity against neuroblastoma cells using whole blood.Rituximab induces phenotypical and functional changes of NK cells in a non-malignant experimental setting.Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients.Effect of Fc-γ Receptor Polymorphism on Rituximab-Mediated B Cell Depletion in ABO-Incompatible Adult Living Donor Liver Transplantation.Controlled Epstein-Barr virus reactivation after allogeneic transplantation is associated with improved survival.Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy.How to outsmart NK cell tolerance.Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity.The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells.Improving the chance of cure of follicular lymphoma by combining immunotherapy and radioimmunotherapy based on anti-CD20 antibodies?

P2860

Q21131216-72AA89B3-AA25-4FE0-8CDE-3C0A7583F18D Q24612811-8B8A7F3D-45CD-40F5-B65D-F46BFC1C5250 Q26795378-A2023857-8014-444D-B2E6-F58FA57ECF22 Q26860800-7DE9EC1D-DFEA-4534-B83B-2691ED5D1C74 Q26991899-5EFFB65A-225C-4BF0-8A96-9E0C58C8D562 Q27694769-AEB5C291-BE53-4E72-B213-8A4745A45C96 Q28087719-1CA8B5BB-F39E-492A-8FDF-BEF6173656E0 Q30408922-F88822FA-5A4D-4240-8639-87B37C86D13D Q30421637-6A3308C6-7FFC-4590-B87C-C9F11193F3E2 Q33840472-FBB1DEF3-0B41-4C81-8FF8-80AA01BA9004 Q34551199-7DD76F01-85EC-4076-A184-07C3C1D87C27 Q34598149-0888F269-68F4-45DC-A03C-D0BF34410368 Q36006440-72733638-6959-4C05-B4A6-579B0C4E9E9C Q36113914-A7ECA2CD-CB70-497E-B43F-9F055AEE4ABD Q36264895-1928985B-B6F8-4B38-84C2-98CF9FE7E919 Q36539682-B32C1F10-40B7-4B52-A566-D94ED0F0EC92 Q36814614-5FF38554-5DF1-402E-AB3D-367049E9CA83 Q37741570-540470A6-EB5C-4E84-A940-57D92746A63E Q37995950-AF102BDC-2D6E-4AC9-8C7A-FAFDB2BEBC3F Q38029985-B1331F17-144D-4DF4-93F4-3C96FF33F45E Q38089599-B4AF4633-3CEC-4FE7-9D65-EE0649337DF9 Q38151057-C8AABF24-FC8D-4578-B2C8-7DDF445229B0 Q38174058-C0FE673D-8335-4FCD-9873-798D90B998FA Q38542034-535ED420-23A1-4599-B930-CB9B3AA2AD7A Q38573785-4E0F5D0F-7199-4C1B-942E-2D7FF6240886 Q38780121-D0A7A035-9E93-41D6-900E-FB8B30699AE4 Q38831202-60729E8B-4944-4264-BCAD-7EBA93060F21 Q38875063-CF631617-49F4-4036-AB90-90C26F35FC0B Q39110347-3E693EC2-841A-4BA3-80AC-4422E8EBB227 Q39224881-74789C43-1376-40D2-B9A0-97EE220306AC Q39389554-F38D3B92-34AC-4516-9F07-66782558E981 Q39834269-6DA60D13-7AEF-47FA-9135-C165809F65A3 Q40170025-A40A3882-A2C6-4D05-A34E-6C98A1A3DCEA Q42244554-D911CC4A-3095-4D56-AB0B-AD1219A9FDC9 Q42358561-DC538C7B-31F6-464C-BB73-1A601435F337 Q42583606-AD386E96-F58C-4F63-B6CE-2B4578B59B22 Q42660162-D9B94966-DDF0-460C-B13A-CEA6D9B409FD Q42660174-547F8A96-3AA5-45DE-800C-949F8DDED875 Q45803486-0889F421-94C3-4A04-B52A-852CECB89248 Q45807575-80F16B8C-E06D-480E-A7E0-62B9B000E294

P2860

Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism.

http://www.wikidata.org/entity/Q35230227

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Rituximab infusion induces NK ...... gh-affinity CD16 polymorphism.

@ast

Rituximab infusion induces NK ...... gh-affinity CD16 polymorphism.

@en

type

label

Rituximab infusion induces NK ...... gh-affinity CD16 polymorphism.

@ast

Rituximab infusion induces NK ...... gh-affinity CD16 polymorphism.

@en

prefLabel

Rituximab infusion induces NK ...... gh-affinity CD16 polymorphism.

@ast

Rituximab infusion induces NK ...... gh-affinity CD16 polymorphism.

@en

P1433

Q35230227-C1080979-0A5C-4B38-B619-6BA0DFD5401D

P1476

Q35230227-842FCCFD-D6B2-4140-9BEC-73F5EC03330A

P2093

Q35230227-303764EE-F2C5-4018-A823-4030CAFDEAEC

Q35230227-401A7D48-265E-4CF2-96BB-93832262A6B7

Q35230227-8D4C2D25-EF62-4676-9E39-D810BDA6EA37

Q35230227-ED2DA2D5-0037-43F7-B809-34CD292E12D3

P2860

Q35230227-06C0B7DA-7757-46BD-850B-DD4E7FBFD213

Q35230227-0B4D387B-BFB0-4327-8C37-0F61FF3E291C

Q35230227-1F656576-60A0-40F7-BB32-9B4D1E74C5C5

Q35230227-2721F7ED-4C00-41CF-86B2-6CB9DEA0D786

Q35230227-3AD59808-D799-4E07-8760-C4062838A5E9

Q35230227-45F06671-A396-432A-8AC9-6BDA4F1A1AC0

Q35230227-4787760C-2CEB-4282-A797-36A5F23A76DE

Q35230227-4A302CA9-0243-4A32-A3B2-A263509CCE50

Q35230227-7042C887-FE48-462B-9278-D198C5AF7942

Q35230227-732ECE4A-99E7-45C6-B689-5F55F83D6B14

P304

Q35230227-92943F85-7CEC-496C-829B-F4F0263970BE

P31

Q35230227-A58AECD9-5F93-404F-8763-A33552DAF4C1

P356

Q35230227-6472B775-196F-49C4-951A-CC4066815963

P407

Q35230227-76C27010-4249-4D94-AC93-DFF95347364D

P433

Q35230227-288F5308-8A66-44C6-998F-979B14A85F6D

P478

Q35230227-4AF9B722-5300-4593-827C-48CE1316860D

P50

Q35230227-1FF5A307-7EFE-4C91-936D-3C713BB8834A

Q35230227-40A47C3A-B5C4-4E9F-8B9A-11381C2D0B5D

Q35230227-447AEC75-16FD-4348-92D4-2393D45B30A5

Q35230227-63D31917-8DD0-4E9F-B970-36338ABFB27E

Q35230227-FE27B69C-5831-487A-BA95-BFA3DB1B76DC

P577

Q35230227-8AA0004E-CE2E-4DB1-9BBF-E389D6CBBC3C

P5875

Q35230227-C17C6EC9-BB28-40C1-9BF9-878E3D39295A

P698

Q35230227-A7E55AA2-8AAD-482F-A556-74FC65F54E37

P932

Q35230227-BDB34979-8B18-4D64-B6D0-34AA6912C3D6

P356

BLOOD-2011-05-351411

P1433

P1476

Rituximab infusion induces NK ...... igh-affinity CD16 polymorphism

@en

P2093

Christopher Dahle

http://www.w3.org/2001/XMLSchema#string

Laura Jacobus

http://www.w3.org/2001/XMLSchema#string

Sue Blackwell

http://www.w3.org/2001/XMLSchema#string

Tina Knutson

http://www.w3.org/2001/XMLSchema#string

P2860

NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.

Rituximab in autoimmune hematologic diseases: not just a matter of B cells.

Rituximab: therapeutic benefit! Vitamin R?

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma

Engineered antibody Fc variants with enhanced effector function.

Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype.

Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model

CD20-targeted therapy: the next generation of antibodies.

Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101.

P304

3347-3349

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-05-351411

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

George J Weiner

Suresh Veeramani

P577

2011-07-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51501407

http://www.w3.org/2001/XMLSchema#string

P698

21768303

http://www.w3.org/2001/XMLSchema#string

P932

3179401

http://www.w3.org/2001/XMLSchema#string